<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146248">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01841086</url>
  </required_header>
  <id_info>
    <org_study_id>KUP-SPG3-101</org_study_id>
    <nct_id>NCT01841086</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 3-Treatment, 3-Period Williams-Design to Assess the Pharmacokinetic Characteristics and Food Effect of Sarpogrelate HCl CR Tablets Compared With Sarpogrelate HCl IR Tablets in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea United Pharm. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea United Pharm. Inc.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics of sarpogrelate
      controlled-release formulation (CR) in comparison to immediate-release formulation (IR) and
      Food effect on the pharmacokinetics of sarpogrelate CR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Active Comparator : predose(0), 0.25, 0.5, 1, 1.5, 2, 3, 6(immediately before 2nd drug intake) , 6.25, 6.5, 7, 7.5, 8, 9, 12(immediately before 3rd drug intake), 12.5, 13, 13.5, 14, 15, 16, 24 hours post-dose Experimental : predose(0), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 hours post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt</measure>
    <time_frame>24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Active Comparator : predose(0), 0.25, 0.5, 1, 1.5, 2, 3, 6(immediately before 2nd drug intake) , 6.25, 6.5, 7, 7.5, 8, 9,12(immediately before 3rd drug intake), 12.5, 13, 13.5, 14, 15, 16, 24 hours post-dose Experimental : predose(0), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 hours post-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax, t1/2</measure>
    <time_frame>24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Active Comparator : predose(0), 0.25, 0.5, 1, 1.5, 2, 3, 6(immediately before 2nd drug intake) , 6.25, 6.5, 7, 7.5, 8, 9, 12(immediately before 3rd drug intake), 12.5, 13, 13.5, 14, 15, 16, 24 hours post-dose Experimental : predose(0), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-âˆž</measure>
    <time_frame>24h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Active Comparator : predose(0), 0.25, 0.5, 1, 1.5, 2, 3, 6(immediately before 2nd drug intake) , 6.25, 6.5, 7, 7.5, 8, 9,12(immediately before 3rd drug intake), 12.5, 13, 13.5, 14, 15, 16, 24 hours post-dose Experimental : predose(0), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24 hours post-dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Anplag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sarpogrelate HCl 300mg once a day or 100mg three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UI03SPG300CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sarpogrelate HCl 300mg once a day or 100mg three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anplag</intervention_name>
    <description>Sarpogrelate HCl 300mg once a day or 100mg three times a day</description>
    <arm_group_label>Anplag</arm_group_label>
    <arm_group_label>UI03SPG300CT</arm_group_label>
    <other_name>Anplag</other_name>
    <other_name>UI03SPG300CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UI03SPG300CT</intervention_name>
    <description>Sarpogrelate HCl 300mg once a day or 100mg three times a day</description>
    <arm_group_label>Anplag</arm_group_label>
    <arm_group_label>UI03SPG300CT</arm_group_label>
    <other_name>UI03SPG300CT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 to 55 years of healthy volunteers

        Exclusion Criteria:

          -  Hypersensitivity Reaction about Sarpogrelate HCl or other antiplatelets
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wooseong Huh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 23, 2013</lastchanged_date>
  <firstreceived_date>April 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarpogrelate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
